Trial Outcomes & Findings for A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism (NCT NCT04111757)

NCT ID: NCT04111757

Last Updated: 2024-06-14

Results Overview

Predictability is defined as the difference between the attempted and achieved manifest refraction spherical equivalent (MRSE) at the time of refractive stability.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

168 participants

Primary outcome timeframe

Assessed at Month 3 to Month 9

Results posted on

2024-06-14

Participant Flow

Unit of analysis: Eyes

Participant milestones

Participant milestones
Measure
Technolas TENEO 317 Model 2
One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0. Technolas® TENEO 317 Model 2: LASIK eye surgery
Overall Study
STARTED
168 333
Overall Study
COMPLETED
168 316
Overall Study
NOT COMPLETED
0 17

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Technolas TENEO 317 Model 2
n=333 Eyes
One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0. Technolas® TENEO 317 Model 2: LASIK eye surgery
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
168 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
32.5 Years
STANDARD_DEVIATION 6.63 • n=5 Participants
Sex: Female, Male
Female
101 Participants
n=5 Participants
Sex: Female, Male
Male
67 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
19 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
149 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=5 Participants
Race (NIH/OMB)
Asian
18 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=5 Participants
Race (NIH/OMB)
White
140 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
3 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=5 Participants
Region of Enrollment
United States
168 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Assessed at Month 3 to Month 9

Predictability is defined as the difference between the attempted and achieved manifest refraction spherical equivalent (MRSE) at the time of refractive stability.

Outcome measures

Outcome measures
Measure
Technolas TENEO 317 Model 2
n=333 Eyes
One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0. Technolas® TENEO 317 Model 2: LASIK eye surgery
Percentage of Eyes That Achieve MRSE Predictability Within ±0.50 Diopter (D) and ±1.00 D
±0.50 Diopter
287 Eyes
Percentage of Eyes That Achieve MRSE Predictability Within ±0.50 Diopter (D) and ±1.00 D
±1.00 Diopter
302 Eyes

PRIMARY outcome

Timeframe: Assessed at Month 3 to Month 9

Percentage of eyes targeted for emmetropia that achieve UDVA of 20/40 or better at the point at which refractive stability is reached.

Outcome measures

Outcome measures
Measure
Technolas TENEO 317 Model 2
n=333 Eyes
One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0. Technolas® TENEO 317 Model 2: LASIK eye surgery
Percentage of Eyes Targeted for Emmetropia That Achieve Uncorrected Distance Visual Acuity (UDVA) of 20/40 or Better
304 Eyes

Adverse Events

Technolas TENEO 317 Model 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Johnson Varughese

Bausch & Lomb

Phone: 9089271162

Results disclosure agreements

  • Principal investigator is a sponsor employee Contact Sponsor directly for details
  • Publication restrictions are in place

Restriction type: OTHER